ReviewJournal of advanced veterinary and animal research2025
The dual role of extracellular vesicles derived from animal and human immune cells: A systematic review.
Review in Journal of advanced veterinary and animal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to examine the functions of extracellular vesicles (EVs) originating from animal and human immune cells, with a focus on their roles in immunomodulation and therapeutic potential. It highlights their dual effects in infection and autoimmunity, cancer treatment, inflammatory conditions, and regenerative medicine while also addressing the challenges in standardizing EV production, isolation, and characterization for clinical applications. This review highlights the need for robust protocols to advance EV-based therapies. It also synthesizes current literature on immune cell-derived EVs, with a focus on their mechanisms of action in intercellular communication, immune modulation, and therapeutic delivery. Additionally, it examines studies that explore the regenerative potential of immune cell-derived EVs and discusses the technical and methodological challenges involved in EV research and clinical translation. EVs from immune cells can either boost or reduce immune responses in tumor therapy, which greatly affects how cancer develops and how well treatments work. These EVs also show promise in managing inflammatory diseases through immune modulation and targeted therapeutic delivery. Furthermore, immune cell-derived EVs possess regenerative properties, contributing to tissue repair and the maintenance of homeostasis. Despite these promising roles, challenges related to the standardization of EV production, isolation, and characterization continue to impede clinical translation, for improved protocols to ensure reproducibility and scalability. Immune cell-derived EVs possess substantial therapeutic potential in cancer treatment, inflammatory diseases, and regenerative medicine. These tiny membrane-bound particles, naturally released by immune cells, carry bioactive molecules that can modulate immune responses, suppress tumor growth, or promote tissue repair. However, before these therapies can be widely used in clinics, key challenges must be addressed, particularly in standardizing their production, characterization, and quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.